Efficacy of Sertraline in the Treatment of Children and Adolescents with Major Depressive Disorder: Two Randomized Controlled Trials

Karen Wagner, Paul Ambrosini, Moira Rynn, Christopher Wohlberg, Ruoyong Yang, Michael S. Greenbaum, Ann Childress, Craig Donnelly, Deborah Deas

Research output: Contribution to journalArticle

322 Citations (Scopus)

Abstract

Context: The efficacy, safety, and tolerability of selective serotonin reuptake inhibitors (SSRIs) in the treatment of adults with major depressive disorder (MDD) are well established. Comparatively few data are available on the effects of SSRIs in depressed children and adolescents. Objective: To evaluate the efficacy and safety of sertraline compared with placebo in treatment of pediatric patients with MDD. Design and Setting: Two multicenter randomized, double-blind, placebo-controlled trials were conducted at 53 hospital, general practice, and academic centers in the United States, India, Canada, Costa Rica, and Mexico between December 1999 and May 2001 and were pooled a priori. Participants: Three hundred seventy-six children and adolescents aged 6 to 17 years with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-defined MDD of at least moderate severity. Intervention: Patients were randomly assigned to receive a flexible dosage (50-200 mg/d) of sertraline (n=189) or matching placebo tablets (n=187) for 10 weeks. Main Outcome Measures: Change from baseline in the Children's Depression Rating Scale-Revised (CDRS-R) Best Description of Child total score and reported adverse events. Results: Sertraline-treated patients experienced statistically significantly greater improvement than placebo patients on the CDRS-R total score (mean change at week 10, -30.24 vs -25.83, respectively; P=.001; overall mean change, -22.84 vs -20.19, respectively; P=.007). Based on a 40% decrease in the adjusted CDRS-R total score at study end point, 69% of sertraline-treated patients compared with 59% of placebo patients were considered responders (P=.05). Sertraline treatment was generally well tolerated. Seventeen sertraline-treated patients (9%) and 5 placebo patients (3%) prematurely discontinued the study because of adverse events. Adverse events that occurred in at least 5% of sertraline-treated patients and with an incidence of at least twice that in placebo patients included diarrhea, vomiting, anorexia, and agitation. Conclusion: The results of this pooled analysis demonstrate that sertraline is an effective and well-tolerated short-term treatment for children and adolescents with MDD.

Original languageEnglish (US)
Pages (from-to)1033-1041
Number of pages9
JournalJournal of the American Medical Association
Volume290
Issue number8
DOIs
StatePublished - Aug 27 2003

Fingerprint

Sertraline
Major Depressive Disorder
Randomized Controlled Trials
Placebos
Therapeutics
Serotonin Uptake Inhibitors
Depression
Safety
Costa Rica
Anorexia
Mexico
Diagnostic and Statistical Manual of Mental Disorders
General Practice
Tablets
Canada
Vomiting
India
Diarrhea
Outcome Assessment (Health Care)
Pediatrics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Efficacy of Sertraline in the Treatment of Children and Adolescents with Major Depressive Disorder : Two Randomized Controlled Trials. / Wagner, Karen; Ambrosini, Paul; Rynn, Moira; Wohlberg, Christopher; Yang, Ruoyong; Greenbaum, Michael S.; Childress, Ann; Donnelly, Craig; Deas, Deborah.

In: Journal of the American Medical Association, Vol. 290, No. 8, 27.08.2003, p. 1033-1041.

Research output: Contribution to journalArticle

Wagner, Karen ; Ambrosini, Paul ; Rynn, Moira ; Wohlberg, Christopher ; Yang, Ruoyong ; Greenbaum, Michael S. ; Childress, Ann ; Donnelly, Craig ; Deas, Deborah. / Efficacy of Sertraline in the Treatment of Children and Adolescents with Major Depressive Disorder : Two Randomized Controlled Trials. In: Journal of the American Medical Association. 2003 ; Vol. 290, No. 8. pp. 1033-1041.
@article{d9cdcba10fc84cd98555ea592aa470a3,
title = "Efficacy of Sertraline in the Treatment of Children and Adolescents with Major Depressive Disorder: Two Randomized Controlled Trials",
abstract = "Context: The efficacy, safety, and tolerability of selective serotonin reuptake inhibitors (SSRIs) in the treatment of adults with major depressive disorder (MDD) are well established. Comparatively few data are available on the effects of SSRIs in depressed children and adolescents. Objective: To evaluate the efficacy and safety of sertraline compared with placebo in treatment of pediatric patients with MDD. Design and Setting: Two multicenter randomized, double-blind, placebo-controlled trials were conducted at 53 hospital, general practice, and academic centers in the United States, India, Canada, Costa Rica, and Mexico between December 1999 and May 2001 and were pooled a priori. Participants: Three hundred seventy-six children and adolescents aged 6 to 17 years with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-defined MDD of at least moderate severity. Intervention: Patients were randomly assigned to receive a flexible dosage (50-200 mg/d) of sertraline (n=189) or matching placebo tablets (n=187) for 10 weeks. Main Outcome Measures: Change from baseline in the Children's Depression Rating Scale-Revised (CDRS-R) Best Description of Child total score and reported adverse events. Results: Sertraline-treated patients experienced statistically significantly greater improvement than placebo patients on the CDRS-R total score (mean change at week 10, -30.24 vs -25.83, respectively; P=.001; overall mean change, -22.84 vs -20.19, respectively; P=.007). Based on a 40{\%} decrease in the adjusted CDRS-R total score at study end point, 69{\%} of sertraline-treated patients compared with 59{\%} of placebo patients were considered responders (P=.05). Sertraline treatment was generally well tolerated. Seventeen sertraline-treated patients (9{\%}) and 5 placebo patients (3{\%}) prematurely discontinued the study because of adverse events. Adverse events that occurred in at least 5{\%} of sertraline-treated patients and with an incidence of at least twice that in placebo patients included diarrhea, vomiting, anorexia, and agitation. Conclusion: The results of this pooled analysis demonstrate that sertraline is an effective and well-tolerated short-term treatment for children and adolescents with MDD.",
author = "Karen Wagner and Paul Ambrosini and Moira Rynn and Christopher Wohlberg and Ruoyong Yang and Greenbaum, {Michael S.} and Ann Childress and Craig Donnelly and Deborah Deas",
year = "2003",
month = "8",
day = "27",
doi = "10.1001/jama.290.8.1033",
language = "English (US)",
volume = "290",
pages = "1033--1041",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "8",

}

TY - JOUR

T1 - Efficacy of Sertraline in the Treatment of Children and Adolescents with Major Depressive Disorder

T2 - Two Randomized Controlled Trials

AU - Wagner, Karen

AU - Ambrosini, Paul

AU - Rynn, Moira

AU - Wohlberg, Christopher

AU - Yang, Ruoyong

AU - Greenbaum, Michael S.

AU - Childress, Ann

AU - Donnelly, Craig

AU - Deas, Deborah

PY - 2003/8/27

Y1 - 2003/8/27

N2 - Context: The efficacy, safety, and tolerability of selective serotonin reuptake inhibitors (SSRIs) in the treatment of adults with major depressive disorder (MDD) are well established. Comparatively few data are available on the effects of SSRIs in depressed children and adolescents. Objective: To evaluate the efficacy and safety of sertraline compared with placebo in treatment of pediatric patients with MDD. Design and Setting: Two multicenter randomized, double-blind, placebo-controlled trials were conducted at 53 hospital, general practice, and academic centers in the United States, India, Canada, Costa Rica, and Mexico between December 1999 and May 2001 and were pooled a priori. Participants: Three hundred seventy-six children and adolescents aged 6 to 17 years with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-defined MDD of at least moderate severity. Intervention: Patients were randomly assigned to receive a flexible dosage (50-200 mg/d) of sertraline (n=189) or matching placebo tablets (n=187) for 10 weeks. Main Outcome Measures: Change from baseline in the Children's Depression Rating Scale-Revised (CDRS-R) Best Description of Child total score and reported adverse events. Results: Sertraline-treated patients experienced statistically significantly greater improvement than placebo patients on the CDRS-R total score (mean change at week 10, -30.24 vs -25.83, respectively; P=.001; overall mean change, -22.84 vs -20.19, respectively; P=.007). Based on a 40% decrease in the adjusted CDRS-R total score at study end point, 69% of sertraline-treated patients compared with 59% of placebo patients were considered responders (P=.05). Sertraline treatment was generally well tolerated. Seventeen sertraline-treated patients (9%) and 5 placebo patients (3%) prematurely discontinued the study because of adverse events. Adverse events that occurred in at least 5% of sertraline-treated patients and with an incidence of at least twice that in placebo patients included diarrhea, vomiting, anorexia, and agitation. Conclusion: The results of this pooled analysis demonstrate that sertraline is an effective and well-tolerated short-term treatment for children and adolescents with MDD.

AB - Context: The efficacy, safety, and tolerability of selective serotonin reuptake inhibitors (SSRIs) in the treatment of adults with major depressive disorder (MDD) are well established. Comparatively few data are available on the effects of SSRIs in depressed children and adolescents. Objective: To evaluate the efficacy and safety of sertraline compared with placebo in treatment of pediatric patients with MDD. Design and Setting: Two multicenter randomized, double-blind, placebo-controlled trials were conducted at 53 hospital, general practice, and academic centers in the United States, India, Canada, Costa Rica, and Mexico between December 1999 and May 2001 and were pooled a priori. Participants: Three hundred seventy-six children and adolescents aged 6 to 17 years with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-defined MDD of at least moderate severity. Intervention: Patients were randomly assigned to receive a flexible dosage (50-200 mg/d) of sertraline (n=189) or matching placebo tablets (n=187) for 10 weeks. Main Outcome Measures: Change from baseline in the Children's Depression Rating Scale-Revised (CDRS-R) Best Description of Child total score and reported adverse events. Results: Sertraline-treated patients experienced statistically significantly greater improvement than placebo patients on the CDRS-R total score (mean change at week 10, -30.24 vs -25.83, respectively; P=.001; overall mean change, -22.84 vs -20.19, respectively; P=.007). Based on a 40% decrease in the adjusted CDRS-R total score at study end point, 69% of sertraline-treated patients compared with 59% of placebo patients were considered responders (P=.05). Sertraline treatment was generally well tolerated. Seventeen sertraline-treated patients (9%) and 5 placebo patients (3%) prematurely discontinued the study because of adverse events. Adverse events that occurred in at least 5% of sertraline-treated patients and with an incidence of at least twice that in placebo patients included diarrhea, vomiting, anorexia, and agitation. Conclusion: The results of this pooled analysis demonstrate that sertraline is an effective and well-tolerated short-term treatment for children and adolescents with MDD.

UR - http://www.scopus.com/inward/record.url?scp=0042922806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042922806&partnerID=8YFLogxK

U2 - 10.1001/jama.290.8.1033

DO - 10.1001/jama.290.8.1033

M3 - Article

C2 - 12941675

AN - SCOPUS:0042922806

VL - 290

SP - 1033

EP - 1041

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 8

ER -